Union Minister Ashwini Vaishnaw announced that India's Semicon 2.0 will focus on full product development, prioritizing ...

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral ...

Selecting the right software development agency is one of the most critical decisions a business can make. It’s a choice that ...

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK’s ...

HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / / Medicus Pharma Ltd. ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

BNB surges past $900 to $920 following Franklin Templeton partnership. Strong institutional demand and market momentum hint ...

When design environments function seamlessly, engineers spend time engineering instead of wrestling with files or tools.

Despite the acquisition, Statsig will retain its operational independence, continuing to function out of its Seattle office. This approach allows OpenAI to benefit from Statsig's specialized knowledge ...

Traditional microbial expression systems can be advanced through improved plasmid replication, target gene transcription, ...

The U.S. military’s technical engineers begin their careers at Fort Leonard Wood during advanced individual training to learn ...